Hyperimmune Globulins Market Report 2026

The hyperimmune globulins market size has grown strongly in recent years. It will grow from $2.06 billion in 2025 to $2.21 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to established use in rabies and tetanus prophylaxis, increasing incidence of infectious diseases, reliance on plasma-derived therapies, government immunization programs, growth of hospital-based emergency care.

The hyperimmune globulins market size is expected to see strong growth in the next few years. It will grow to $2.86 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to rising organ transplantation rates, increasing outbreaks of viral infections, expansion of plasma donation infrastructure, advancements in purification technologies, growing focus on rapid immune protection. Major trends in the forecast period include rising demand for passive immunization therapies, increased use in post-exposure prophylaxis, growing adoption in transplant and immunocompromised care, expansion of plasma collection and fractionation capacity, strengthening of regulatory oversight and quality standards.

The rising prevalence of infectious diseases is expected to drive the growth of the hyperimmune globulins market in the coming years. Infectious diseases are caused by harmful agents, such as viruses, bacteria, fungi, and parasites. Factors such as antimicrobial resistance, climate change, and population growth contribute to their increasing prevalence. Hyperimmune globulins provide immediate passive immunity by delivering concentrated antibodies against specific pathogens, aiding in the prevention or treatment of diseases like rabies, hepatitis B, and tetanus. For example, in August 2024, the UK Health Security Agency reported that in 2023, the West Midlands region recorded the highest number of measles cases at 160 (44%), followed by London with 122 cases (33%). Children under 10 years accounted for 63% of total cases, totaling 232, with measles activity peaking in December at 157 new cases compared to 45 in November. Therefore, the rising prevalence of infectious diseases is driving the hyperimmune globulins market.

Government-led research and development initiatives in healthcare are also expected to boost the hyperimmune globulins market. Such initiatives are increasing in response to the demand for innovative medical solutions and the need to address emerging health challenges. By supporting the development and accessibility of hyperimmune globulins, governments help combat specific infectious diseases effectively. For instance, in May 2024, the UK Office for National Statistics reported that total healthcare expenditure grew by 5.6% from 2022 to 2023, a substantial acceleration compared to 0.9% growth in 2022. Therefore, rising government initiatives in healthcare R&D are propelling the hyperimmune globulins market.

The growing incidence of autoimmune diseases is further expected to propel market growth. Autoimmune diseases occur when the immune system mistakenly attacks the body’s healthy tissues, and their prevalence is rising due to environmental triggers such as pollution and chemical exposure. Hyperimmune globulins help manage these conditions by supplying concentrated antibodies that modulate abnormal immune responses. For instance, in August 2024, Public Health Scotland reported that the Scottish Multiple Sclerosis Register recorded 455 newly diagnosed MS patients in 2023. Therefore, the increasing incidence of autoimmune diseases is driving the hyperimmune globulins market.

Major companies operating in the hyperimmune globulins market are Bayer AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Ltd., Fresenius Kabi AG, Grifols SA, Octapharma AG, Shanghai RAAS Blood Products Co. Ltd., Emergent BioSolutions Inc., Kedrion Biopharma Inc., LFB SA, Hualan Biological Engineering Inc., Taibang Biologic Group, Bio Products Laboratory (BPL) Ltd., ADMA Biologics, Cangene Corporation, Kamada Ltd., Saol Therapeutics Inc., Shire, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.

North America was the largest region in the hyperimmune globulins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperimmune globulins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hyperimmune globulins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the hyperimmune globulins market by increasing costs for imported plasma derivatives, fractionation equipment, and cold-chain logistics, impacting overall production economics. These effects are most pronounced in regions dependent on cross-border plasma sourcing and biologics imports, including parts of Asia-Pacific and Latin America. At the same time, tariffs are encouraging domestic plasma collection, local manufacturing investments, and regional self-sufficiency, creating long-term opportunities for supply chain resilience and market expansion.

The hyperimmune globulins market research report is one of a series of new reports that provides hyperimmune globulins market statistics, including hyperimmune globulins industry global market size, regional shares, competitors with a hyperimmune globulins market share, detailed hyperimmune globulins market segments, market trends and opportunities, and any further data you may need to thrive in the hyperimmune globulins industry. This hyperimmune globulins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hyperimmune globulins are specialized immunoglobulin preparations enriched with antibodies targeting a specific pathogen or antigen. These products are derived from the plasma of individuals with high levels of antibodies against a particular infectious agent or toxin. Hyperimmune globulins are primarily used for passive immunization, providing immediate immunity in situations where rapid protection is required.

The main types of hyperimmune globulins include hepatitis B hyperimmune globulin, rabies hyperimmune globulin, tetanus hyperimmune globulin, cytomegalovirus (CMV) hyperimmune globulin, varicella-zoster virus (VZV) hyperimmune globulin, respiratory syncytial virus (RSV) hyperimmune globulin, and others. Hepatitis B hyperimmune globulin, for example, is derived from plasma donors with high antibody titers against the hepatitis B virus. These products are administered via various routes, including intramuscular and intravenous injection, and are used across multiple applications such as government healthcare programs, private healthcare facilities, and other sectors.

The hyperimmune globulins market consists of sales of bayrab, hepaGam B, Tetanus Immune Globulin (TIG), variZIG, respiGam, and cytogam. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.